These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26686797)

  • 21. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
    Robinson JC
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Generic drug prescribing: pilot study on the impact of the new drug pricing system on costs and potential savings].
    Wasserfallen JB; Shimia S; Biollaz J; Pannatier A
    Rev Med Suisse; 2006 Mar; 2(59):865-6, 868-71. PubMed ID: 16646370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Financing pharmaceuticals in transition economies.
    Kanavos P
    Croat Med J; 1999 Jun; 40(2):244-59. PubMed ID: 10234068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?
    Granlund D; Koksal-Ayhan MY
    Eur J Health Econ; 2015 Dec; 16(9):969-83. PubMed ID: 25404013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005.
    Koskinen H; Martikainen JE; Maljanen T
    Clin Ther; 2009 Jun; 31 Pt 1():1469-77. PubMed ID: 19698904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
    Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
    Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of generic reference pricing interventions in the statin market.
    Puig-Junoy J
    Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Reference Pricing with Drug Selection and Spending.
    Robinson JC; Whaley CM; Brown TT
    N Engl J Med; 2017 Aug; 377(7):658-665. PubMed ID: 28813219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of generic reference pricing in Italy, a decade on.
    Ghislandi S; Armeni P; Jommi C
    Eur J Health Econ; 2013 Dec; 14(6):959-69. PubMed ID: 23183986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pricing and competition in the private dental market in Finland.
    Widström E; Väisänen A; Mikkola H
    Community Dent Health; 2011 Jun; 28(2):123-7. PubMed ID: 21780350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
    Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
    CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generic Medicine Pricing Policies in Europe: Current Status and Impact.
    Dylst P; Simoens S
    Pharmaceuticals (Basel); 2010 Mar; 3(3):471-481. PubMed ID: 27713264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of reference pricing: implications for US prescription drug spending.
    Lee JL; Fischer MA; Shrank WH; Polinski JM; Choudhry NK
    Am J Manag Care; 2012 Nov; 18(11):e429-37. PubMed ID: 23198752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Number of manufacturers and generic drug pricing from 2005 to 2017.
    Hernandez I; Good CB; Gellad WF; Parekh N; He M; Shrank WH
    Am J Manag Care; 2019 Jul; 25(7):348-352. PubMed ID: 31318508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies.
    Cohen JT
    Value Health; 2023 Mar; 26(3):344-350. PubMed ID: 36336585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of reference-pricing systems in Europe: a literature review and case studies.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):729-37. PubMed ID: 22098289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.